Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

AltaRex in-licenses antibody from NIH for AIT platform

Jan. 14, 2000

Ligand sells Marathon assets to CoPharma

Jan. 14, 2000

Japanese marketing approval no longer sought for Mochida's TNF

Jan. 12, 2000

FDA grants priority review status to Wyeth-Ayerst's therapy for relapsed adult AML

Jan. 11, 2000

New developments announced for AltaRex's ovarian cancer therapy

Jan. 6, 2000

Maxamine granted orphan drug status for AML

Jan. 5, 2000

Cell Genesys receives payment from Japan Tobacco

Jan. 3, 2000

Cel-Sci completes another study in head and neck cancer

Dec. 29, 1999

Impressive early phase II clinical data reported for OvaRex in relapsed ovarian cancer

Dec. 29, 1999

Biomira's BLP25 liposome technology offers promise as cancer therapy

Dec. 29, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...